肝细胞肝癌患者抗凝血酶Ⅲ的测定及意义

The detection of antithrombin Ⅲ and its clinical significance in patients with hepatocellular carcinoma

目的研究抗凝血酶Ⅲ(ATⅢ)在肝癌患者和非肝癌患者的活性差异。方法回顾性分析2017年1月至2018年12月治疗肝癌患者95例及非肝癌患者212例,收集各组的临床资料,测量所有患者的ATⅢ活性,比较两组间ATⅢ活性的差异。结果肝癌组ATⅢ活性(U/d L)为73.88+22.03,相对非肝癌组(87.92+19.09),ATⅢ活性低且差异有统计学意义。结论肝癌患者ATⅢ活性低于非肝癌组且差异有统计学意义。对肝癌患者测定ATⅢ活性有一定临床意义。

Objective To investigate the difference in antithrombin Ⅲ(AT Ⅲ) activity between hepatocellular carcinoma(HCC) patients and non-HCC patients. Methods The clinical data, including AT Ⅲactivity, of 95 HCC patients and 212 non-HCC patients, who received treatment during the period from January 2017 and December 2018, were retrospectively analyzed. The AT Ⅲ activity was detemined in all patients. The difference in AT Ⅲ activity between the two groups was evaluated. Results The AT Ⅲ activity in HCC group was(73.88±22.03) IU/dL, which was lower than(87.92±19.09) U/dL in non-HCC group, the difference between the two groups was statistically significant. Conclusion The AT Ⅲ level in HCC patients is significantly lower than that in non-HCC patients, therefore, the determination of AT Ⅲ activity in HCC patients has certain clinical significance.